Johnson & Johnson to Acquire Ambrx Biopharma for $2 Billion to Advance Next-Generation Antibody-Drug Conjugates

Johnson & Johnson recently announced that it has reached a definitive agreement to acquire Ambrx Biopharma (referred to as Ambrx, NASDAQ stock exchange code: AMAM). Ambrx is a clinical-stage biopharmaceutical company that utilizes a synthetic biology technology platform to design and develop next-generation antibody-drug conjugates (ADCs). Under the all-cash transaction terms, Johnson & Johnson will acquire Ambrx at an equity value of approximately $2 billion, with an estimated net cash acquisition value of about $1.9 billion.

Ambrx Biopharma is currently focusing on advancing a series of clinical and preclinical programs to optimize the efficacy and safety of its therapeutic candidates across multiple cancer indications. These include ARX517, an ADC targeting PSMA for metastatic castration-resistant prostate cancer (mCRPC); ARX788, an ADC targeting human epidermal growth factor receptor 2 (HER2) for metastatic HER2+ breast cancer; and ARX305, an ADC targeting CD-70 for renal cell carcinoma.

The acquisition within this program provides Johnson & Johnson with a unique opportunity to design, develop, and commercialize targeted oncology therapies. Ambrx's proprietary ADC technology combines the advantages of highly specific targeting monoclonal antibodies, successfully linking chemotherapy drug payloads to achieve efficient targeted elimination of cancer cells while avoiding common side effects associated with traditional chemotherapy. Building on Johnson & Johnson’s innovative achievements in oncology and prostate cancer, Johnson & Johnson scientists will collaborate with Ambrx researchers to accelerate the Phase 1/2 APEX-01 study (NCT04662580) of ARX517 for advanced prostate cancer and advance the development of a pipeline of novel ADC candidates.

Ambrx spun off from The Scripps Research Institute in 2003. The company pioneered the use of an expanded genetic code technology platform to incorporate synthetic amino acids (SAAs) into proteins at any specified position using industry-standard cell lines. SAAs enable engineered precision biologics to have specific, uniform, and stable conjugation, overcoming the limitations of traditional conjugation technologies.

Editor: Mu Mian

Disclaimer: This article is a reprint from Yaozhi.com. All rights to the images and text belong to the original author. The purpose of the reprint is to convey more information and does not represent the views of this platform. If there are any issues regarding content, copyright, or other aspects, please leave a message on this platform, and we will address it promptly.